Microsomal triglyceride transfer protein (MTP) is a heterodimer chaperone made up of a 55-kDa protein disulfide isomerase (PDI) and a 97-kDa lipid-binding and -transfer subunit. MTP was initially discovered to be a resident protein of the endoplasmic reticulum (ER) that aids in the transfer of neutral lipids to developing apolipoprotein B (apoB). The assembly and secretion of VLDL and chylomicrons by the liver and intestine, respectively, depend on MTP, which is mainly expressed in hepatocytes and enterocytes.Patients with abetalipoproteinemia, who have mutations in MTP and have no apoB-containing lipoproteins in the circulation, have been found to have its crucial role in the assembly and secretion of apoB-containing lipoproteins. It is now known that MTP plays a part in the biosynthesis of cholesterol ester and the cluster of differentiation 1d (CD1d), in addition to its role in the transfer of neutral lipids. MTP may aid in the transfer of sphingolipids like ceramides and sphingomyelin to the apoB-containing lipoproteins in addition to neutral lipids.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V3504 | Lomitapide | 182431-12-5 | Lomitapide (formerly known as AEGR-733; BMS-201038; Juxtapid; Lojuxta) is a novel, oral and potent inhibitor of microsomal triglyceride-transfer protein (MTP) approved as a lipid-lowering agent for the treatment of homozygous familial hypercholesterolemia. |
|
V3505 | Lomitapide mesylate | 202914-84-9 | Lomitapide mesylate (AEGR733 mesylate; BMS201038; Juxtapid; Lojuxta), the mesylate salt ofLomitapide, is a microsomal triglyceride-transfer protein (MTP) inhibitor that has been approved by FDA as a lipid-lowering agent to treat homozygous familial hypercholesterolemia. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
